Clinical Evidence

The Research Behind TAKE

TAKE was formulated around the clinical evidence on what GLP-1 treatment does to the body, not around what sells. This page is the source documentation behind every product claim on this site.

GLP-1 Nutritional Consequences: Foundational Research

Caloric restriction during GLP-1 treatment. Research published in Obesity Reviews (2026) confirmed that calorie intake can drop by 16 to 39% during GLP-1 treatment and that there has been very little clinical study of how GLP-1 medications affect overall diet quality, protein intake, or micronutrient intake. This finding is the clinical foundation for the entire TAKE product line.

Lean mass loss during GLP-1 treatment. Multiple analyses of semaglutide and tirzepatide trial data have documented that lean muscle mass accounts for up to 40% of total weight lost during GLP-1 treatment. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed 14.9% average total body weight loss on semaglutide 2.4mg over 68 weeks. Subsequent body composition analyses from trial substudies confirmed significant lean mass loss in the absence of active protective interventions.

Semaglutide efficacy: STEP 1 trial. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. Key finding: 14.9% average body weight reduction at 68 weeks with semaglutide 2.4mg weekly versus 2.4% with placebo.

Tirzepatide efficacy: SURMOUNT-1 trial. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. Key finding: 22.5% average body weight reduction at 72 weeks with tirzepatide 15mg weekly. The largest average weight loss recorded in a pharmacological obesity trial at time of publication.

Weight regain after stopping GLP-1 medications. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. Key finding: Two thirds of weight lost during semaglutide treatment was regained within one year of stopping medication.

Creatine Monohydrate: TAKE Build

Creatine and lean mass preservation during caloric restriction. Hultman E et al. Muscle creatine loading in men. Journal of Applied Physiology. 1996;81(1):232-237. Established the foundational protocol of 5g creatine daily for muscle phosphocreatine saturation. Extensively replicated across subsequent research.

International Society of Sports Nutrition position stand on creatine. Kreider RB et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition. 2017;14:18. Key finding: creatine monohydrate is the most effective ergogenic nutritional supplement for increasing high-intensity exercise capacity and lean body mass during training. 5g daily is the evidence-supported maintenance dose.

Ginger Root Extract: TAKE Flow

Ginger for nausea. Lete I, Allue J. The Effectiveness of Ginger in the Prevention of Nausea and Vomiting during Pregnancy and Chemotherapy. Integrative Medicine Insights. 2016;11:11-17. Systematic review confirming ginger root extract reduces nausea across multiple clinical contexts through gastric motility support.

Ginger and gastric emptying. Wu KL et al. Effects of ginger on gastric emptying and motility in healthy humans. European Journal of Gastroenterology and Hepatology. 2008;20(5):436-440. Key finding: ginger significantly accelerated gastric emptying compared to placebo, directly relevant to the mechanism of GLP-1-induced nausea.

Probiotics: TAKE Flora

Probiotic delivery and stomach acid survival. Govinden U et al. Encapsulation of Lactobacillus acidophilus ATCC 4356 in alginate-based capsules for improved gastrointestinal delivery. Journal of Microencapsulation. 2014. Established the evidence base for marine polysaccharide delivery systems (the technology behind TAKE Flora's MAKTREK Bi-Pass system) for improving probiotic viability through gastric acid.

Ashwagandha and 5-HTP: TAKE Rest

KSM-66 Ashwagandha and cortisol reduction. Chandrasekhar K et al. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine. 2012;34(3):255-262. Key finding: KSM-66 Ashwagandha significantly reduced serum cortisol levels and perceived stress scores versus placebo.

5-HTP and serotonin synthesis. Birdsall TC. 5-Hydroxytryptophan: A Clinically-Effective Serotonin Precursor. Alternative Medicine Review. 1998;3(4):271-280. Established 5-HTP as a direct precursor to serotonin synthesis, bypassing the dietary tryptophan pathway and supporting sleep onset and sleep architecture.

Melatonin and sleep. Brzezinski A et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Medicine Reviews. 2005;9(1):41-50. Meta-analysis of 17 studies confirming exogenous melatonin significantly reduces sleep onset latency and improves sleep quality.

Peptides and Hair Growth: TAKE Regrowth

Rosemary extract and hair growth. Panahi Y et al. Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed. 2015;13(1):15-21. Key finding: rosemary oil was as effective as minoxidil 2% for hair growth at 6 months with significantly fewer side effects including scalp itching.

Telogen effluvium and rapid weight loss. Guo EL, Katta R. Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatology Practical and Conceptual. 2017;7(1):1-10. Clinical review establishing the relationship between rapid caloric restriction, micronutrient depletion, and telogen effluvium onset and severity.

Vitamin D Deficiency

Prevalence of vitamin D deficiency. Forrest KY, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency in US adults. Nutrition Research. 2011;31(1):48-54. Key finding: 41.6% of US adults are vitamin D deficient. Reduced food intake during GLP-1 treatment compounds this already widespread deficit.

A note on clinical interpretation

TAKE products are dietary supplements. The research listed on this page supports the ingredient choices in each product but does not constitute a claim that TAKE products diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any new supplement. These statements have not been evaluated by the Food and Drug Administration.

For questions about the research behind a specific product, contact care@takecomplete.com.

These statements have not been evaluated by the Food and Drug Administration. TAKE products are not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any new supplement.